芪参通脉丸防治冠脉支架后再狭窄346例患者临床观察  

Clinical Observation of 346 Cases of Coronary Ctent Restenosis After Coronary Stenting

作　　者：李卫华[1] 

机构地区：[1]安钢职工总医院,安阳455000

出　　处：《中国卫生标准管理》2015年第27期126-127,共2页China Health Standard Management

摘　　要：目的研究芪参通脉丸在冠脉支架后再狭窄的临床防治效果。方法选取冠脉支架植入成功的患者346例,在患者的预后过程中分为治疗组和对照组各173例,对照组组使用常规药物治疗预防,治疗组在常规治疗基础上同步联合使用芪参通脉丸,跟踪观察半年内患者的心绞痛发作情况、心电图指标水平,并对患者的再狭窄情况进行检查。结果治疗后治疗组患者的心绞痛发生次数少于对照组患者,患者的再狭窄情况少于对照组患者,两组相比差异有统计学意义(P<0.05)。结论在冠心病患者进行冠脉支架手术之后可以同步使用芪参通脉丸进行预后防治治疗,减轻患者的心绞痛发作几率和再狭窄情况的发生。Objective To study the clinical effect of the treatment of restenosis after coronary stenting in patients with coronary artery stenosis. Methods 346 patients with coronary stent implantation were successful,and according to the prognosis of patients,they were divided into treatment group and control group,173 cases each group. The treatment group was treated with conventional therapy. Results The number of angina pectoris in treatment group was less than that of the control group,and the patients in restenosis were less than those in the control group,and the difference was statistically significant（P〈0.05）in the two groups. Conclusion Patients with coronary heart disease after coronary stenting can be carried out with the use of Qishentongmai to prevent and treat the prognosis.

关 键 词：冠脉内支架置入术 再狭窄 芪参通脉丸 临床观察 

分 类 号：R541.4[医药卫生—心血管疾病]